BR112023017434A2 - Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3 - Google Patents

Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3

Info

Publication number
BR112023017434A2
BR112023017434A2 BR112023017434A BR112023017434A BR112023017434A2 BR 112023017434 A2 BR112023017434 A2 BR 112023017434A2 BR 112023017434 A BR112023017434 A BR 112023017434A BR 112023017434 A BR112023017434 A BR 112023017434A BR 112023017434 A2 BR112023017434 A2 BR 112023017434A2
Authority
BR
Brazil
Prior art keywords
nlrp3
oxo
modulate
alkoxy
pyridazine derivatives
Prior art date
Application number
BR112023017434A
Other languages
English (en)
Inventor
Daniel Oehlrich
Van Rompaey Dries
Jesús Alcázar Vaca Manuel
Lourdes Linares De La Morena Maria
Eric Muratore Michael
Luc Maria Van Gool Michiel
Mohamed Lamkanfi
Van Opdenbosch Nina
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023017434A2 publication Critical patent/BR112023017434A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3. a presente invenção se refere a compostos para uso como inibidores da produção de inflamassoma nlrp3, em que tais compostos são como definidos pelos compostos da fórmula (i), e em que os números inteiros r1, r2, r3 e r4 são definidos na descrição, e em que os compostos podem ser úteis como medicamentos, por exemplo, para uso no tratamento de uma doença ou distúrbio que está associado à atividade de inflamassoma nlrp3.
BR112023017434A 2021-03-04 2022-03-03 Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3 BR112023017434A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21160668 2021-03-04
PCT/EP2022/055432 WO2022184842A1 (en) 2021-03-04 2022-03-03 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3

Publications (1)

Publication Number Publication Date
BR112023017434A2 true BR112023017434A2 (pt) 2023-09-26

Family

ID=74858295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017434A BR112023017434A2 (pt) 2021-03-04 2022-03-03 Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3

Country Status (10)

Country Link
US (1) US20240109905A1 (pt)
EP (1) EP4301753A1 (pt)
JP (1) JP2024508017A (pt)
KR (1) KR20230152016A (pt)
CN (1) CN117083272A (pt)
AU (1) AU2022231379A1 (pt)
BR (1) BR112023017434A2 (pt)
CA (1) CA3208988A1 (pt)
MX (1) MX2023010310A (pt)
WO (1) WO2022184842A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203429A1 (en) * 2007-10-31 2010-07-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
WO2017210685A1 (en) * 2016-06-03 2017-12-07 An2H Discovery Limited Pyradazinone derivatives and the compositions and methods of treatment regarding the same
ES2927851T3 (es) 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
EP3817817A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
JP7320595B2 (ja) 2018-07-20 2023-08-03 エフ． ホフマン－ラ ロシュ アーゲー インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物
AU2019309727B2 (en) 2018-07-25 2021-12-23 Novartis Ag NLRP3 inflammasome inhibitors
US20220098188A1 (en) 2018-08-17 2022-03-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
JP2024508017A (ja) 2024-02-21
US20240109905A1 (en) 2024-04-04
AU2022231379A1 (en) 2023-10-19
CA3208988A1 (en) 2022-09-09
CN117083272A (zh) 2023-11-17
KR20230152016A (ko) 2023-11-02
MX2023010310A (es) 2023-09-12
EP4301753A1 (en) 2024-01-10
WO2022184842A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
BR112022023271A2 (pt) Compostos
BR112022020776A2 (pt) Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3
BR112022020798A2 (pt) Compostos tricíclicos como inibidores de nlrp3
BR112022021881A2 (pt) Novos compostos de triazinoindol
BR112022020807A2 (pt) Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BR112022022761A2 (pt) Inibidor de sos1 contendo fósforo
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112022021514A2 (pt) [1,3]diazino[5,4-d]pirimidinas como inibidores de her2
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112022024045A2 (pt) Moduladores il-17a
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022023983A2 (pt) Compostos terapêuticos
BR112022021370A2 (pt) Composto, e, método de tratamento de uma doença ou distúrbio
BR112023006312A2 (pt) Composto, métodos para preparar o composto, composição farmacêutica e uso do composto
BR112016008158A2 (pt) Moduladores de ror-gama-t de quinolinila ligados a metileno
BR112023018655A2 (pt) Compostos antibacterianos
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112022016432A2 (pt) Compostos heterocíclicos de heteroarila e usos dos mesmos